Table 2.

Changes in PDE4A activity

Control	(100)
GH alone	177  ±  12
GH + chelerythrine HCl (5 μM)	173  ±  10
GH + PD 98059 (20 μM)	186  ±  14
GH + wortmannin (50 nM)	106  ±  6
GH + LY 294002 (2 μM)	107  ±  12
GH + rapamycin (10 nM)	88  ±  10
GH + actinomycin D (4 μg/ml)	180  ±  18
JAK2 antisense	68  ±  3
GH + JAK2 antisense	73  ±  10
JAK-2 scrambled	96  ±  14
GH + JAK-2 scrambled	179  ±  5
Δ p85 PI3 kinase	104  ±  3
GH + Δ p85 PI3 kinase	90  ±  10
Activated p70 S6 kinase	143  ±  10
Activated p70 S6 kinase + rapamycin	153  ±  7
GH + activated p70 S6 kinase	189  ±  14
Wild-type p70 S6 kinase	95  ±  11
GH + wild-type p70 S6 kinase	167  ±  12
GH + wild-type p70 S6 kinase + rapamycin	97  ±  12

These data describe changes in the immunoprecipitated PDE4A activity of F442A cells. Identical numbers of cells were analyzed under conditions where all the PDE4A was immunoprecipitated. Data are means ± SD for n = 5 experiments. Basal PDE4A activity in the immunoprecipitates was 2.1 ± 0.1 pmol/min/mg of protein. Total rolipram-inhibited PDE4 activity was 4.5 ± 0.9 pmol/min/mg of protein. Total cilostimide-inhibited PDE3 activity was 3.3 ± 0.2 pmol/min/mg of protein. Changes in PDE4A activity are given relative to control set at 100%. Cells were treated with ligands for 30 min.